Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinson’s disease

Kabra, Atul; Baghel, Uttam Singh; Hano, Christophe; Martins, Natália; Khalid, Mohammad; Sharma, Rohit

doi:10.1016/j.jaim.2020.06.007

Cited by 19 publications

(9 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Trevitt et al., 2009; Maj et al., 1990; Juszkiewicz et al., 1994; Juszkiewicz et al., 1995; Mandhane et al., 1997; Konieczny et al., 1999; Jagtap & Inamdar, 2001; Ossowska et al., 2001; Breysse et al., 2002; Moo‐Puc et al., 2003; Ossowska et al., 2003; Rukoyatkina et al., 2003; Wardas et al., 2003; Tanganelli et al., 2004; Ossowska et al., 2005; Zazpe et al., 2006; Lopez et al., 2007; Sibille et al., 2007; Ahemad et al., 2009; Beurrier et al., 2009; Góngora‐Alfaro et al., 2009; Konieczny et al., 2009; Ardashov et al., 2011; Joshi et al., 2011; Trevizol et al., 2011; Lopez et al., 2012; Shyamjith et al., 2012; Goudet et al., 2012; Acuña‐Lizama et al., 2013; Konieczny & Lenda, 2013; Atack et al., 2014; Ittiyavira & Ruby, 2014; Azam, et al., 2009; Zheng et al., 2014; Gmiro et al., 2015; Maurice et al., 2015; Nade et al., 2015; Bhangale & Acharya, 2016; Dhingra & Gahalain, 2016; Basu et al., 2017; Chitra et al., 2017; Gupta et al., 2017; Kumari et al., 2017; Kronbauer et al., 2017; Tian et al., 2017; Yang et al., 2016; Engelhardt et al., 2018; Slee et al., 2008; Saleem et al., 2019; Kabra et al., 2020; Łażewska et al., 2020; Chiu et al., 1981; Schmidt & Bubser, 1989; Schmidt et al., 1991; Kretschmer, 1994; Kretschmer et al.,…”

Section: Resultsmentioning

confidence: 99%

“…The variation in publications per year is important data. As noted, the haloperidol‐induced catalepsy model for parkinsonism was first applied in the early 1980s (Chiu et al., 1981; Pycock et al., 1982; Schallert & Teitelbaum, 1981; Scheel‐Krüger & Magelund, 1981) and is still widely used nowadays (Bhattamisra et al., 2020; Chaudhary & Dhande, 2020; Kabra et al., 2020; Łażewska et al., 2020; Olaya et al., 2020; Parambi et al., 2020; Pardo et al., 2020; Sanawar et al., 2020; Sharma et al., 2020; Sita et al., 2020). In fact, since 2000, the number of articles published using this model has increased and become more constant (Figure 2).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Waku

Magalhães

Alves

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

Several useful animal models for parkinsonism have been developed so far. Haloperidol‐induced catalepsy is often used as a rodent model for the study of motor impairments observed in Parkinson's disease and related disorders and for the screening of potential antiparkinsonian compounds. The objective of this systematic review is to identify publications that used the haloperidol‐induced catalepsy model for parkinsonism and to explore the methodological characteristics and the main questions addressed in these studies. A careful systematic search of the literature was carried out by accessing articles in three different databases: Web of Science, PubMed and SCOPUS. The selection and inclusion of studies were performed based on the abstract and, subsequently, on full‐text analysis. Data extraction included the objective of the study, study design and outcome of interest. Two hundred and fifty‐five articles were included in the review. Publication years ranged from 1981 to 2020. Most studies used the model to explore the effects of potential treatments for parkinsonism. Although the methodological characteristics used are quite varied, most studies used Wistar rats as experimental subjects. The most frequent dose of haloperidol used was 1.0 mg/kg, and the horizontal bar test was the most used to assess catalepsy. The data presented here provide a framework for an evidence‐based approach to the design of preclinical research on parkinsonism using the haloperidol‐induced catalepsy model. This model has been used routinely and successfully and is likely to continue to play a critical role in the ongoing search for the next generation of therapeutic interventions for parkinsonism.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Waku

Magalhães

Alves

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…The mechanism of action of haloperidol is associated with the blockade of dopamine receptors, central alphaadrenoblocking action and disruption of the process of reverse neuronal capture and deposition of adrenaline. Unfortunately, the use of haloperidol is limited by the side effects of the drug, in particular extrapyramidal disorders (Kabra et al 2020).…”

Section: Experimental Modelmentioning

confidence: 99%

Investigation of antiparkinsonian activity of new imidazole-4,5-dicarboxylic acid derivatives on the experimental model of catalepsy

Dergachev

Yakovleva

Brusina

et al. 2023

RRP

View full text Add to dashboard Cite

Introduction: To study the antiparkinsonian activity of new ligands of the glutamate NMDA receptor complex – 1,2–substituted imidazole-4,5-dicarboxylic acids – on an experimental model of catalepsy caused by haloperidolintraabdominal injections in rats. Materials and methods: The experiments were performed on Wistar rats weighing 300-350 g, obtained from the Rappolovo nursery of the Russian Academy of Medical Sciences (Leningrad Region). The animals were kept in standard plastic cages in vivarium conditions with free access to water and food at a temperature of 22±2 °C and in the experiment were divided into several groups (6 animals each). All the experiments were carried out in the autumn-winter period. The animals were kept in accordance with the rules of laboratory practice (GLP), regulatory documents ”Sanitary Rules for the Device, Equipment and Maintenance of Vivarium” and the Order of the Ministry of Health and Social Development of the Russian Federation dated 23.08.2010 No. 708n “On Approval of the Rules of Laboratory Practice”. Imidazole-dicarboxylic acid derivatives (IEM-2295, IEM-2296) were injected intraperitoneally at doses from 5 mg/kg to 40 mg/kg simultaneously with haloperidol at a dose of 1 mg/kg, after which the duration and severity of catalepsy were evaluated after 30, 60, 120 minutes from 0 to 6 points according to the Morpurgo method. Results: The severity of catalepsy with the injection of IEM-2295 decreased on average to 3 points, while in the control group it remained at the level of 6 points throughout the observation. However, the severity of catalepsy with the introduction of IEM-2296 decreased to an average of 4 points, but the effect itself lasted longer than with the introduction of IEM-2295. Thus, it was noted that by the 120th minute of observation, the severity of catalepsy in rats receiving the IEM-2295 compound averaged 5 points, whereas in animals receiving IEM-2296 – 3 points. Discussion: Basing on the results of our work and similar experiments, we can conclude that the studied compounds, which are not channel blockers, have an active effect on dopaminergic neurotransmission, because of which the symptoms of catalepsy that occur when haloperidol is injected to rats were stopped to one degree or another. Conclusion: The studied substances exhibit antiparkinsonian activity on an experimental haloperidol model of catalepsy in rats and are promising for development as potential therapies for neurodegenerative diseases. Further study of these compounds and other ligands from the NMDA-blocker group in a wider sample on the catalepsy model, as well as on other models of Parkinsonism, is required. Graphical Abstract

show abstract

“… 18 Different studies have revealed that haloperidol-induced catalepsy presents a robust model to investigate the anti-parkinsonian activity. 19 However, other chemicals like rotenone and paraquat were also used to induce the PD, 20 but in this study, haloperidol is used for the Parkinsonism model. The advantage of haloperidol-induced parkinsonism is that haloperidol blocks the D 2 receptors and causes the depletion of dopamine.…”

Section: Introductionmentioning

confidence: 98%

“…Haloperidol is an antipsychotic drug used for the treatment of schizophrenia by blocking the dopamine receptors and increasing its metabolism, resulting in the generation of hydrogen peroxide and ROS, and hence causing neurotoxicity and oxidative stress . Different studies have revealed that haloperidol-induced catalepsy presents a robust model to investigate the anti-parkinsonian activity . However, other chemicals like rotenone and paraquat were also used to induce the PD, but in this study, haloperidol is used for the Parkinsonism model.…”

Section: Introductionmentioning

confidence: 99%

Parkinsonism Attenuation by Antihistamines via Downregulating the Oxidative Stress, Histamine, and Inflammation

et al. 2022

View full text Add to dashboard Cite

Parkinson disease (PD) is a neurodegenerative disorder of the motor activity of the brain, regulated by dopaminergic neurons of substantia nigra, resulting in an increased density of histaminergic fibers. This study was aimed to evaluate the effects of H1 antagonist’s ebastine and levocetirizine in PD per se and in combination. Animals were divided into 9 groups ( n = 10). Group 1 received carboxymethyl cellulose CMC (1 mL/kg). Group II was treated with haloperidol (1 mg/kg) (diseased group). Group III was treated with levodopa/carbidopa (levo 20 mg/kg). Groups IV and V were treated with ebastine at dose levels of 2 and 4 mg/kg, respectively. Groups VI and VII were treated with levocetirizine at dose levels of 0.5 and 1 mg/kg, respectively. Group VIII was treated with ebastine (4 mg/kg) + levo (20 mg/kg) in combination. Group IX was treated with levocetirizine (1 mg/kg) + levo (20 mg/kg). PD was induced with haloperidol (1 mg/kg iv, once daily for 23 days) for a duration of 30 min. Behavioral tests like rotarod, block and triple horizontal bars, actophotometer, and open field were performed. Biochemical markers of oxidative stress, i.e., SOD, CAT, GSH, MDA, dopamine, serotonin, and nor-adrenaline and nitrite, were determined. Histamine, mRNA expression of α-synuclein, and TNF-α level in the serum and brain of mice were analyzed. Endogenous biochemical markers were increased except mRNA expression of α-synuclein, which was reduced. In combination therapy with the standard drug, ebastine (4 mg/kg) significantly improved the cataleptic state and dopamine levels, but no significant difference in the renal and liver functioning tests was observed. This study concluded that ebastine (4 mg/kg) might work in the treatment of PD as it improves the cataleptic state in haloperidol-induced catalepsy.

show abstract

Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinson’s disease

Cited by 19 publications

References 56 publications

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Investigation of antiparkinsonian activity of new imidazole-4,5-dicarboxylic acid derivatives on the experimental model of catalepsy

Parkinsonism Attenuation by Antihistamines via Downregulating the Oxidative Stress, Histamine, and Inflammation

Contact Info

Product

Resources

About